14d
Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma
OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...
Broad Drug Portfolio Targets Fragile-X Mental Retardation Protein (FMRP) in Cancer, Bromo and Extra Terminal (BET) Domain Proteins, Colony-stimulating Factor 1 Receptor (CSF1R), and Additional Cancer ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two ...
SOUTH SAN FRANCISCO, Calif., January 21, 2026--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today ...
SOUTH SAN FRANCISCO, Calif., November 04, 2025--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced ...
Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET ...
Opna Bio AG has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular ...
Recent patents from Opna Bio AG detail new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic ...
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results